lobbying_activities: 3434586

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3434586	a48c52fc-d7fa-4ee5-abc0-84c11e631f7f	Q3	CAPITOL COUNSEL LLC	313715	ALNYLAM PHARMACEUTICALS, INC.	2025	third_quarter	MED	Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.	Food & Drug Administration (FDA)	30000		0	0	2025-10-15T15:19:15-04:00